Literature DB >> 22969921

TNF-α -863 polymorphisms and the risk of hepatocellular carcinoma.

Yan Yang1, Xiao-Qiang Qiu, Hong-Ping Yu, Xiao-Yun Zeng, Chun-Hua Bei.   

Abstract

Hepatocellular carcinoma (HCC) is a common type of highly malignant tumor. Guangxi is an area of China characterized by a high incidence of HCC. Previous epidemiological studies have found that chronic infection with hepatitis B virus (HBV) is one of the major etiological risk factors for HCC in China. With the increased understanding of the host immune response against HBV and the pathogenesis of the virus, at present, greater attention is being given to the immune response of cytokine genes, as polymorphisms may have a major impact on the course and outcome of HBV infection. In the present study, we genotyped tumor necrosis factor-α (TNF-α) rs1800629 (-308G/A), rs1800630 (-863C/A); interleukin-1B rs1143627 (-31T/C); and transforming growth factor β1 (TGF-β1) rs1800469 (-509C/T) in a hospital-based study of 772 HCC cases and 852 cancer-free controls. The distribution of the frequency of TNF-α rs1800630 sites of CC, CA, AA were 65.67, 27.46 and 6.87% in the case group, respectively, as compared with 67.02, 29.58 and 3.40% in the controls, all with a statistical significance (P<0.05). The logistic regression analysis revealed that the variant rs1800630 AA genotypes were associated with a significantly increasing risk of HCC (OR=2.058, 95% CI 1.289-3.287), compared with the wild-type rs1800630 CC. Further stratified analyses showed that after stratification for history of alcohol drinking, in a subgroup of individuals without a history of drinking, the HCC risk in the group with the TNF-α rs1800630 A allele was 1.839 times higher than that in the group with TNF-α rs1800630 C (P<0.010). These findings suggest that TNF-α rs1800630 may contribute to the risk of HCC, however, these data require further validation.

Entities:  

Year:  2011        PMID: 22969921      PMCID: PMC3438725          DOI: 10.3892/etm.2011.418

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

Review 1.  Management of hepatitis B: 2000--summary of a workshop.

Authors:  A S Lok; E J Heathcote; J H Hoofnagle
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

Review 2.  Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer.

Authors:  J D Groopman; J S Wang; P Scholl
Journal:  Can J Physiol Pharmacol       Date:  1996-02       Impact factor: 2.273

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Immunobiology of persistent blood-borne viral infections.

Authors:  G N Vyas
Journal:  Dev Biol (Basel)       Date:  2000

5.  A common functional polymorphism (C-->A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha.

Authors:  T Skoog; F M van't Hooft; B Kallin; S Jovinge; S Boquist; J Nilsson; P Eriksson; A Hamsten
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

6.  Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population.

Authors:  P Kummee; P Tangkijvanich; Y Poovorawan; N Hirankarn
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

7.  Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene.

Authors:  Sheng-Yow Ho; Ying-Jan Wang; Hen-Li Chen; Chih-Hung Chen; Chih-Jen Chang; Po-Jen Wang; Helen H W Chen; How-Ran Guo
Journal:  Cancer Causes Control       Date:  2004-09       Impact factor: 2.506

8.  -509C>T polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection.

Authors:  Peng Qi; Yue-ming Chen; Hao Wang; Meng Fang; Qiang Ji; Yun-peng Zhao; Xiao-juan Sun; Yan Liu; Chun-fang Gao
Journal:  Cancer Immunol Immunother       Date:  2009-01-25       Impact factor: 6.968

9.  Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection.

Authors:  Yue Wang; Naoya Kato; Yujin Hoshida; Hideo Yoshida; Hiroyoshi Taniguchi; Tadashi Goto; Masaru Moriyama; Motoyuki Otsuka; Shuichiro Shiina; Yasushi Shiratori; Yoichi Ito; Masao Omata
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

10.  The global burden of cancer: priorities for prevention.

Authors:  Michael J Thun; John Oliver DeLancey; Melissa M Center; Ahmedin Jemal; Elizabeth M Ward
Journal:  Carcinogenesis       Date:  2009-11-24       Impact factor: 4.944

View more
  4 in total

1.  TGF-β1 -509C/T (or +869T/C) polymorphism might be not associated with hepatocellular carcinoma risk.

Authors:  Weixing Li; Han Wu; Chao Song
Journal:  Tumour Biol       Date:  2013-05-08

2.  Enhanced circulating transforming growth factor beta 1 is causally associated with an increased risk of hepatocellular carcinoma: a mendelian randomization meta-analysis.

Authors:  Wei-Qun Lu; Ji-Liang Qiu; Zhi-Liang Huang; Hai-Ying Liu
Journal:  Oncotarget       Date:  2016-12-20

3.  Condemned or Not to Die? Gene Polymorphisms Associated With Cell Death in Pemphigus Foliaceus.

Authors:  Valéria Bumiller-Bini; Gabriel Adelman Cipolla; Mariana Basso Spadoni; Danillo Gardenal Augusto; Maria Luiza Petzl-Erler; Marcia Holsbach Beltrame; Angelica Beate Winter Boldt
Journal:  Front Immunol       Date:  2019-10-18       Impact factor: 7.561

4.  Association between five types of Tumor Necrosis Factor-α gene polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Citrawati Dyah Kencono Wungu; Fis Citra Ariyanto; Gwenny Ichsan Prabowo; Retno Handajani
Journal:  BMC Cancer       Date:  2020-11-23       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.